Meglumine antimoniate

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Meglumine antimoniate
Accession Number
DB13732
Description
Not Available
Type
Small Molecule
Groups
Experimental, Investigational
Structure
Thumb
Weight
Average: 365.98
Monoisotopic: 365.00705
Chemical Formula
C7H18NO8Sb
Synonyms
  • Antimoniato de meglumina
  • Glucantim
  • Glucantime
  • Meglumine antimonate
  • Meglumine antimoniate

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Categories

ATC Codes
P01CB01 — Meglumine antimonate
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as hexoses. These are monosaccharides in which the sugar unit is a is a six-carbon containing moeity.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbohydrates and carbohydrate conjugates
Direct Parent
Hexoses
Alternative Parents
Organic antimonates / 1,3-aminoalcohols / Secondary alcohols / Organic antimony salts / 1,2-aminoalcohols / Polyols / Dialkylamines / Primary alcohols / Organopnictogen compounds / Organic oxides
show 1 more
Substituents
1,2-aminoalcohol / 1,3-aminoalcohol / Alcohol / Aliphatic acyclic compound / Amine / Hexose monosaccharide / Hydrocarbon derivative / Organic antimonate / Organic antimony salt / Organic metal salt
show 11 more
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
Not Available

Chemical Identifiers

UNII
75G4TW236W
CAS number
133-51-7
InChI Key
XOGYVDXPYVPAAQ-SESJOKTNSA-M
InChI
InChI=1S/C7H17NO5.H2O.2O.Sb/c1-8-2-4(10)6(12)7(13)5(11)3-9;;;;/h4-13H,2-3H2,1H3;1H2;;;/q;;;;+1/p-1/t4-,5+,6+,7+;;;;/m0..../s1
IUPAC Name
(2R,3R,4R,5S)-6-(methylamino)hexane-1,2,3,4,5-pentol; oxostibinic acid
SMILES
O[Sb](=O)=O.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO

References

General References
Not Available
ChemSpider
58479
RxNav
319866
ChEMBL
CHEMBL239129
Wikipedia
Meglumine_antimoniate

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedTreatmentLeishmaniasis, Cutaneous1
4CompletedTreatmentLocalized Cutaneous Leishmaniasis1
4CompletedTreatmentVisceral Leishmaniasis1
4TerminatedTreatmentVisceral Leishmaniasis1
3CompletedTreatmentLeishmaniasis, Cutaneous3
3Not Yet RecruitingTreatmentCutaneous Leishmaniases1
3TerminatedTreatmentLeishmaniasis, Cutaneous2
3Unknown StatusTreatmentLeishmaniasis, Cutaneous1
2CompletedTreatmentLeishmaniasis1
2CompletedTreatmentLeishmaniasis, Cutaneous1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
SolutionParenteral1.5 g
Injection, solutionIntramuscular1.5 G/5ML
SolutionIntramuscular1.5 g
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility240.0 mg/mLALOGPS
logP-2.4ALOGPS
logP-3.4ChemAxon
logS0.09ALOGPS
pKa (Strongest Acidic)12.65ChemAxon
pKa (Strongest Basic)9.11ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count6ChemAxon
Polar Surface Area113.18 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity44.84 m3·mol-1ChemAxon
Polarizability19.52 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created on June 23, 2017 14:47 / Updated on December 02, 2020 04:50